Cortexyme Inc. logo

Cortexyme (CRTX) stock

CRTX · Cortexyme Inc. · NASDAQ

Website

What is the latest news on CRTX stock?

SECago
Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

All CRTX news

When does Cortexyme report earnings?

The latest Cortexyme earnings release came out on Oct 26, 2021: Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease...

CRTX earnings history

Latest news

25 items

Cortexyme Inc. (CRTX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for CRTX in the last 30 days. The most recent was published Dec 16, 2022.

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX FAQ

7 questions
  • What does Cortexyme Inc. do?
    Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
  • Where does CRTX stock trade?
    Cortexyme Inc. (CRTX) is listed on NASDAQ.
  • What sector and industry is CRTX in?
    Cortexyme Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Cortexyme Inc. go public?
    Cortexyme Inc. (CRTX) completed its IPO in 2019.
  • What are analysts saying about CRTX?
    Across the last 8 analyst actions on Cortexyme Inc., there were 0 upgrades and 5 downgrades. The most recent action was from HC Wainwright & Co.: Buy with a $15.00 price target on 2022-03-09.
  • What companies are similar to CRTX?
    Notable peers in the same industry include EXEL (Exelixis Inc.), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.). Compare CRTX side-by-side with any of them on Quantisnow.
  • How can I track CRTX on Quantisnow?
    Quantisnow aggregates Cortexyme Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRTX to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change